New Nordic Healthbrands (NNH) Q1 2025 earnings summary

Executive summary

• Net sales rose 10.4% year-over-year to 143.8 MSEK, with organic growth of 10.6%.

• Gross margin improved to 64.6% (from 63.4%), and operating profit reached 4.9 MSEK (up from -3.8 MSEK).

• Net profit after tax was 2.7 MSEK, reversing a loss of -3.4 MSEK in Q1 2024.

• Growth was strongest in North America (+20.2%) and the UK (+33% in local currency); Nordic region saw 8.5% growth.

• New product launches and marketing drove sales; several awards and strategic milestones achieved.

Financial highlights

• EBITDA improved to 5.5 MSEK (from -3.3 MSEK), with EBITDA margin at 3.8% (up from -2.5%).

• Cash flow from operating activities was -6.3 MSEK, a significant improvement from -15.8 MSEK year-over-year.

• Gross profit increased to 92.9 MSEK (from 82.6 MSEK), up 12.5%.

• Equity ratio stood at 40.0% (vs. 40.6% last year); net debt slightly decreased to 30.3 MSEK.

• Cash and cash equivalents at quarter-end were 8.2 MSEK (down from 9.9 MSEK).

Outlook and guidance

• Management expects continued revenue growth but notes uncertainty due to new tariffs and unpredictable consumer behavior.

• Focus remains on organic growth, operational efficiency, and increasing EPS for 2025.